BRCA2 and cholangiocarcinoma: The significant difference between the sequencing methods also becomes evident in the example of a patient with cholangiocarcinoma, whose nonfocal loss of chromosome 13, which also affected BRCA2, was used as a co-rationale for PARP inhibition.